New variants of SARS-CoV-2 are a major source of concern, especially for pregnant women and in the perinatal context. The primary aim of this study was to compare the severity of COVID-19 infection in pregnant women depending on strain predominance between wild-type Alpha and Gamma variants. The secondary aim was to study the impact of these strains on obstetrical and neonatal outcomes. We conducted a two-center international retrospective cohort study, which included two type III maternity hospitals, one in France and one in Brazil, comparing the first period corresponding to the wild-type strain and the second period corresponding to the predominance of the Alpha variant in France and the Gamma variant in Brazil. We included 151 pregnant women with symptomatic SARS-CoV-2 infection confirmed by RT-PCR. The rate of severe-to-critical infection, according to the WHO definition, was seven-fold higher in patients infected during the “variant period” than in patients infected during the “wild-type period” (aOR = 7.07, 95CI [2.50–21.6], p < 0.001). There were no statistical differences concerning composite obstetrical and neonatal outcomes between the different periods. While analyzing each variant separately, it was found that, in France, the risk of developing a severe-to-critical infection was three times greater during the Alpha period than during the wild-type period (OR = 3.25, 95CI [0.70–15.6], p = 0.13) and, in Brazil, the risk was twelve times greater during the Gamma period than during the wild-type period (OR = 11.8, 95CI [2.46–72.3], p = 0.003). The Alpha and Gamma variants of SARS-CoV-2 seem to be more dangerous in the obstetrical context. With the rapid emergence of new variants, it is necessary to accelerate vaccination to protect women and newborn children.
There is limited evidence about the use of medications among pregnant women with COVID‐19, as well as risk factors for hospitalization due to COVID‐19 in pregnancy. We aimed to describe the use of medications among SARS‐CoV‐2‐positive pregnant women at the time around infection and identify predictors for hospitalization due to COVID‐19 in two hospitals in Brazil. This is a hospital record‐based study among pregnant women with positive SARS‐CoV‐2 tests between March 2020 and August 2022 from two Brazilian hospitals. Characteristics of sociodemographic, obstetrical, and COVID‐19 symptoms were extracted retrospectively. The prevalence use of medications was based on self‐reported use, and this was administered at the hospital. Logistic regression was used to estimate predictors of hospitalization due to COVID‐19. There were 278 pregnant women included in the study, of which 41 (14.7%) required hospitalization due to COVID‐19. The remaining 237 (85.3%) had mild symptoms or were asymptomatic. Most of the women had the infection in the third trimester (n = 149; 53.6%). The most prevalent medications used across all trimesters were analgesics (2.4% to 20.0%), antibacterials (15.0% to 23.1%), and corticosteroids (7.2% to 10.4%). Pre‐ or gestational hypertensive disorder (odds ratio (OR) 4.94, 95% confidence interval (CI) 1.65, 14.87) and having at least one dose of vaccine against SARS‐CoV‐2 (OR 0.13, 95% CI 0.04, 0.39) were associated with hospitalization due to COVID‐19. Analgesics, antibacterials, and corticosteroids were the most frequently used medications among pregnant women with COVID‐19. Women with hypertensive disorders have almost a five‐fold increased risk of hospitalization due to COVID‐19. Vaccination was the strongest protective factor for severe COVID‐19. The COVID‐19 vaccination among pregnant women should be promoted, and pregnant women diagnosed with COVID‐19 who have hypertensive disorders should be closely monitored.
Background: Chronic pain affects up to 30% of pregnant individuals globally and substantially impairs maternal well‐being. The prevalence and contributing factors of de novo chronic pain in pregnancy (DNPAP) remain poorly studied, with previous chronic pain rarely distinguished from newly arising pain. We examined the prevalence and characteristics of DNPAP and its association with foetal and maternal factors, including dysmenorrhea, depressive symptoms and maternal‐foetal attachment. Methods: This cross‐sectional study included 207 pregnant women between 30 and 34 weeks of gestation. Assessments comprised pain measures (Douleur Neuropathique‐4, McGill Pain Questionnaire, Brief Pain Inventory and Pain Catastrophizing Scale) and maternal well‐being measures (Edinburgh Postnatal Depression Scale, Maternal‐Foetal Attachment Scale and Prenatal Psychosocial Profile). Women with DNPAP were compared with those without chronic pain to identify associated factors. Results: De novo pain was reported by 20.7% of participants, with 59.6% describing it as moderate to severe. DNPAP was significantly associated with higher depressive symptoms, lower maternal‐foetal attachment and a history of dysmenorrhea. Mediation analyses identified depressive symptoms as a key factor linking foetal malformations and gestational diseases to de novo pain. Conclusion: Depression, reduced maternal‐foetal attachment and a history of dysmenorrhea were significantly associated with de novo pain during pregnancy. Depressive symptom severity mediated the relationship between foetal malformations or gestational diseases and DNPAP. Clear characterization of pregnancy‐related pain can inform preventive and therapeutic strategies to improve maternal health outcomes. Significance Statement: This study is the first to report the prevalence of de novo chronic pain during pregnancy, which was found to be high affecting 20.7% of the pregnant women. De novo chronic pain in pregnancy is directly associated with depressive symptoms and is mediated by depressive symptoms in cases involving foetal malformation diagnosis and the presence of gestational diseases. A history of dysmenorrhea is significantly associated with the development of de novo chronic pain in pregnancy, suggesting potential shared underlying mechanisms that open possibilities for testing new early‐detection, therapeutic, and prognostication approaches to pain across women's life‐cycle.